Compare CDZI & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | FBRX |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | 31 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.8M | 487.2M |
| IPO Year | N/A | 2017 |
| Metric | CDZI | FBRX |
|---|---|---|
| Price | $4.02 | $17.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | ★ 785.6K | 225.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $12.97 | N/A |
| Revenue Next Year | $102.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $9.12 |
| 52 Week High | $6.96 | $35.80 |
| Indicator | CDZI | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 40.37 |
| Support Level | $3.42 | $17.33 |
| Resistance Level | $5.12 | $22.84 |
| Average True Range (ATR) | 0.26 | 1.34 |
| MACD | -0.02 | 0.34 |
| Stochastic Oscillator | 26.99 | 45.44 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, generating maximum revenue engaged in providing water filtration solutions for impaired or contaminated groundwater sources.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.